Clinical Trials Browser

Hodgkin Disease × tafasitamab × 30 days × Clear all

NCT05615636 2026-03-16

A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

Phase 2 Recruiting

Hodgkin Disease, Lymphoma, B-Cell